Note 7 - Licences, Royalty Collaborative and Contractual Arrangements (Tables)

9 Months Ended

Mar. 31, 2013

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	Three Months Ended March 31,
	2013		2012
	(in millions)
Royalty revenue  – RelenzaTM		$1.7		$1.7
– Inavir®		3.2		3.6
Commercial milestone – Inavir®		2.9		-
Service revenue under BARDA contract		4.5		1.7
Revenue under other contracts, grants and collaborations		0.2		0.1
Total revenue		$12.5		$7.1

	Nine Months Ended March 31,
	2013		2012
	(in millions)
Royalty revenue  – RelenzaTM		$2.7		$2.4
– Inavir®		4.1		4.3
Commercial milestone – Inavir®		2.9		-
Service revenue under BARDA contract		13.7		6.2
Revenue under other contracts, grants and collaborations		1.0		0.4
Total revenue		$24.4		$13.3